Teva Announces That Azilect® (Rasagiline) Is Approved For Marketing In Israel

Jerusalem, Israel, January 3, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the Israeli Ministry Of Health has issued a marketing authorization for Azilect® (rasagiline) for the treatment of Parkinson's disease both as initial monotherapy in patients with early PD and as adjunct treatment in moderate-to-advanced disease. Following the receipt of this license, Azilect® will be launched in Israel in March 2005. "We are extremely pleased to have received the first approval for the marketing of Azilect® here in Israel where the product originated and was developed. With additional approvals anticipated in other countries during 2005, Azilect® should become an important treatment option for patients suffering from Parkinson's disease," said Israel Makov, President and CEO of Teva. About Azilect® Azilect® is a novel, potent, second-generation, selective, irreversible monoamine oxidase type-B (MAO-B) inhibitor that blocks the breakdown of dopamine, a substance in the brain needed to facilitate movement. The development of rasagiline is part of a long-term alliance for co-development in Parkinson's disease and European marketing between Lundbeck and Teva. Azilect® is a joint development of Teva and the Technion - Israel institute of Technology. About Parkinson's disease Parkinson's disease is a chronic, progressive neurodegenerative condition. The exact cause of PD is not known and is believed to be multifactorial involving genes, environmental factors and aging. Symptoms include tremor, slowness of movement, stiffness, gait and posture problems. As the disease progresses, symptoms worsen, the patient is likely to experience motor complications. Eventually, the disease impairs the patient's ability to function. PD affects men and women equally, and an estimated four million people worldwide suffer from the disease. The disease typically occurs at a late age, affecting approx. 1% of the population over the age of 65. Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe. Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products (so called "authorized generics") or successfully extend the exclusivity period of their branded products, the effects of competition on Copaxone® sales, including potential competition from the expected launch of Tysabri®/Antegren®, Teva's ability to rapidly integrate the operations of acquired businesses, including its acquisition of Sicor Inc., regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to completion of appellate litigation, including that relating to Neurontin, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. View All News Quick links Quarterly Results Events and Presentations Shareholder Meetings ESG Debt Securities SEC Filings Investor FAQ Email alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. At Teva Pharmaceutical Industries Ltd., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to Teva Pharmaceutical Industries Ltd. to send you the requested Investor Email Alert updates. * Required Email Address * Mailing Lists * Press Releases Events SEC Filings Financial Reports Enter the code shown above. * Email Alert Sign Up Confirmation IR Inquiries IR Contacts Interactive Financial Reports At Teva, we strive to deliver quality medicines to patients around the world with integrity and ethical business practices. What we do is important, but how we do it is just as important. Learn more: Teva Code of Conduct Teva Code of Conduct Supplier Code of Conduct Supplier Code of Conduct Social Impact Positions and Policies Social Impact Positions and Policies All Corporate Governance & Policy Documents All Corporate Governance & Policy Documents Contact Us Terms of Use Data Privacy PhV privacy Notice Cookie Settings Teva api Social Media Guidelines Follow us Facebook Linkedin © - Teva Pharmaceutical Industries Ltd Powered By Q4 Inc. 5.184.0.5 (opens in new window)

The release as fetched from its publisher. tevapharm.com ↗